OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
Jostein Starrfelt, Anders Skyrud Danielsen, Eirik Alnes Buanes, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Jostein Starrfelt, Anders Skyrud Danielsen, Eirik Alnes Buanes, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 187
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 187
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 175
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 175
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 162
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 162
Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients
Robert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcárcel Salamanca, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 871-878
Open Access | Times Cited: 47
Robert Whittaker, Anja Bråthen Kristofferson, Beatriz Valcárcel Salamanca, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 871-878
Open Access | Times Cited: 47
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 779-811
Open Access | Times Cited: 10
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 779-811
Open Access | Times Cited: 10
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e074325-e074325
Open Access | Times Cited: 20
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e074325-e074325
Open Access | Times Cited: 20
Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022
Håkon Bøas, Margrethe Larsdatter Storm, German Tapia, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Håkon Bøas, Margrethe Larsdatter Storm, German Tapia, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024
Guiling Zhou, Nina Dael, Stefan Verweij, et al.
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240222-240222
Open Access
Guiling Zhou, Nina Dael, Stefan Verweij, et al.
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240222-240222
Open Access
Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece
Helena C. Maltezou, Dimitrios Basoulis, Konstantinos Bonelis, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2343-2348
Open Access | Times Cited: 11
Helena C. Maltezou, Dimitrios Basoulis, Konstantinos Bonelis, et al.
Vaccine (2023) Vol. 41, Iss. 14, pp. 2343-2348
Open Access | Times Cited: 11
Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage
Vladimir A. Atanasov, Natalia Barreto, Jeff Whittle, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 379-379
Open Access | Times Cited: 10
Vladimir A. Atanasov, Natalia Barreto, Jeff Whittle, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 379-379
Open Access | Times Cited: 10
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 10
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 10
Effectiveness of mRNA Booster Vaccination Against Mild, Moderate, and Severe COVID-19 Caused by the Omicron Variant in a Large, Population-Based, Norwegian Cohort
Ida Laake, Siri N. Skodvin, Kristine Blix, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1924-1933
Open Access | Times Cited: 15
Ida Laake, Siri N. Skodvin, Kristine Blix, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 11, pp. 1924-1933
Open Access | Times Cited: 15
Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
Petter Langlete, Martin Tesli, Lamprini Veneti, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3923-3929
Open Access | Times Cited: 7
Petter Langlete, Martin Tesli, Lamprini Veneti, et al.
Vaccine (2023) Vol. 41, Iss. 26, pp. 3923-3929
Open Access | Times Cited: 7
Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records
Vladimir A. Atanasov, Natalia Barreto, Jeff Whittle, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 971-971
Open Access | Times Cited: 7
Vladimir A. Atanasov, Natalia Barreto, Jeff Whittle, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 971-971
Open Access | Times Cited: 7
Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study
Hannah Chung, Peter C. Austin, Kevin A. Brown, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 11
Hannah Chung, Peter C. Austin, Kevin A. Brown, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 11
Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022
Irina Kislaya, Alexis Sentís, Jostein Starrfelt, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 11
Open Access | Times Cited: 5
Irina Kislaya, Alexis Sentís, Jostein Starrfelt, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 11
Open Access | Times Cited: 5
Estimating vaccine effectiveness against COVID-19 using cause-specific sick leave as an indicator: a nationwide population-based cohort study, Norway, July 2021 – December 2022
Hinta Meijerink, Lamprini Veneti, Anja Bråthen Kristoffersen, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Hinta Meijerink, Lamprini Veneti, Anja Bråthen Kristoffersen, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023
Elina Seppälä, Jesper Dahl, Lamprini Veneti, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 620-628
Open Access | Times Cited: 4
Elina Seppälä, Jesper Dahl, Lamprini Veneti, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 620-628
Open Access | Times Cited: 4
Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel
Helena C. Maltezou, Maria N. Gamaletsou, Theodoros V. Giannouchos, et al.
Journal of Hospital Infection (2022) Vol. 132, pp. 46-51
Open Access | Times Cited: 7
Helena C. Maltezou, Maria N. Gamaletsou, Theodoros V. Giannouchos, et al.
Journal of Hospital Infection (2022) Vol. 132, pp. 46-51
Open Access | Times Cited: 7
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela Rose, Nathalie Nicolay, Virginia Martin, et al.
Eurosurveillance (2023) Vol. 28, Iss. 47
Open Access | Times Cited: 3
Angela Rose, Nathalie Nicolay, Virginia Martin, et al.
Eurosurveillance (2023) Vol. 28, Iss. 47
Open Access | Times Cited: 3
Measuring vaccine protection when the population is mostly vaccinated
Yair Goldberg, Ofra Amir, Micha Mandel, et al.
Journal of Clinical Epidemiology (2023) Vol. 163, pp. 111-116
Closed Access | Times Cited: 2
Yair Goldberg, Ofra Amir, Micha Mandel, et al.
Journal of Clinical Epidemiology (2023) Vol. 163, pp. 111-116
Closed Access | Times Cited: 2
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Vaccine effectiveness in preventing deaths in people with severe acute respiratory syndrome due to COVID-19 in Blumenau, Brazil, 2021
Emanuelle Renck, Caroline Beatriz Zipper, Marcio Rodrigues Fabrino, et al.
Epidemiologia e Serviços de Saúde (2024) Vol. 33
Open Access
Emanuelle Renck, Caroline Beatriz Zipper, Marcio Rodrigues Fabrino, et al.
Epidemiologia e Serviços de Saúde (2024) Vol. 33
Open Access
